NeurAxis, Inc. NRXS

CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company’s commercial functions, including sales and marketing. The appointment of Mr. Blanchard as Chief Commercial Officer

Total national coverage footprint for PENFS increases to over 120 million covered livesCARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”). The c

CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026. Company Webcast The webcast presentation will take place

RALEIGH, NC / ACCESS Newswire / September 15, 2026 / today announced the start of its Virtual Best Ideas Fall Investment Conference, bringing together small and microcap public companies and investors for two days of company presentations and curated one-on-one meetings. The updated presentation schedule appears below.

RALEIGH, NC / ACCESS Newswire / September 8, 2026 / today announced that it will host its Virtual Best Ideas Fall Investment Conference on September 15-16, 2026, bringing together small and microcap public companies and investors for two days of company presentations and 1x1 meetings.The conference will begin on Tuesday, September 15, 2026, with a series of live-streamed company presentations.

Moby summary of NeurAxis, Inc.'s Q2 2026 earnings call

Neuraxis Inc (NRXS) reports record Q2 growth with gross margins expanding to 85.9% while strategically investing in VA channel expansion and large payer negotiations.

Conference call will be held today, Tuesday, August 11 at 9:00 am ETCARMEL, Ind., Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter period ended June 30, 2026. 2Q26 Financial Highlights Revenues increased 116% year over year to $1.9M, reflecting continued growth fr

CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-A

CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am E

Moby summary of NeurAxis, Inc.'s Q1 2026 earnings call

Neuraxis Inc (NRXS) reports significant revenue growth and strategic expansions, while navigating insurance coverage hurdles and financial adjustments.